Getein Biotech(SH:603387)2025-04-29 15:20Financial Performance - The company's operating revenue for 2024 was CNY 1,164,798,937.40, a decrease of 14.93% compared to CNY 1,369,162,256.52 in 2023[22]. - Net profit attributable to shareholders for 2024 was CNY 223,636,488.43, down 20.06% from CNY 279,771,914.08 in 2023[22]. - The basic earnings per share for 2024 was CNY 0.44, reflecting a decline of 20.00% from CNY 0.55 in 2023[23]. - The cash flow from operating activities increased by 26.94% to CNY 422,998,055.82 in 2024, compared to CNY 333,220,661.81 in 2023[24]. - The company's total assets at the end of 2024 were CNY 3,707,374,587.49, a decrease of 1.70% from CNY 3,771,626,052.94 at the end of 2023[22]. - The weighted average return on equity for 2024 was 8.64%, down from 11.17% in 2023, a decrease of 2.53 percentage points[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 202,042,109.65, a decrease of 16.33% from CNY 241,487,200.13 in 2023[22]. - The company reported a loss of CNY 8,087,939.59 from the disposal of non-current assets in 2024[29]. - The total cash dividends distributed during the reporting period amounted to RMB 91,287,633.06, representing 40.82% of the net profit attributable to shareholders of the listed company[6]. - The company achieved total revenue of CNY 1,164,798,937.40, a year-on-year decrease of 14.93%[79]. - The company's net profit attributable to shareholders was CNY 22,363.65 million, down 20.06% year-on-year[79]. Research and Development - The company invested 207 million RMB in R&D in 2024, focusing on chemiluminescence instruments, line systems, and core raw materials, resulting in 373 new patent authorizations[41]. - The company is focusing on R&D investments in molecular diagnostic systems and smart laboratories, integrating AI-assisted diagnostic technology with hardware[72]. - The company plans to continue increasing investment in R&D projects to enhance product performance and reduce production costs[43]. - The company has 497 R&D personnel, accounting for 25.53% of the total workforce[96]. - The company emphasizes continuous R&D innovation as a core driver, enhancing comprehensive innovation capabilities to expand terminal coverage in the clinical diagnostic market[70]. Product Development and Innovation - The company launched the fully automated biochemical analyzer CM800 with a throughput of 800 tests per hour, featuring 137 sample positions and 114 reagent positions[60]. - The Metis6000 fully automated biochemical immunoassay line was installed nearly 90 times in 2024, with a total of about 140 installations since its launch, 70% of which were in secondary and lower-level hospitals[36]. - The company has established eight major technology platforms, including POCT, chemiluminescence, biochemical testing, and molecular testing, expanding from low-throughput to high-throughput automated systems[57]. - The company has transitioned from a single POCT product line to a diverse product range, including chemiluminescence and biochemical products, and is expanding into both tiered hospitals and overseas markets[57]. - The company launched the GN7120 fully automatic nucleic acid amplification analyzer, enhancing its product matrix for small and medium hospitals[74]. Market Presence and Expansion - The company has expanded its overseas market presence to cover 130 countries and regions, establishing good cooperation with local distributors and healthcare institutions[64]. - The company plans to expand its overseas market presence, particularly promoting its small luminescence products MAGICL6000 and MAGICL6000i across Europe, Africa, Asia, and Latin America[116]. - The company has established over 2,000 product import licenses in 66 countries as of December 31, 2024, enhancing its international market presence[45]. - The overseas revenue from conventional products reached 137 million RMB, representing a year-on-year growth of 4.53%[44]. - The company has installed nearly 40 units of the CM-400 and approximately 70 units of the MAGICL6000 and MAGICL6000i in overseas markets, indicating strong growth potential[45]. Governance and Compliance - The company has established an independent financial department with a complete accounting system, ensuring financial independence[129]. - The company maintains independent operations with no shared bank accounts with controlling shareholders[130]. - The company has a complete and independent asset structure, with no instances of fund or asset occupation by controlling shareholders[128]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[127]. - The company has implemented internal control systems to ensure effective management of subsidiaries and mitigate operational risks[167]. Environmental and Social Responsibility - The company invested 512,300 RMB in environmental protection during the reporting period[172]. - The company ensures that wastewater meets the required standards before being discharged, with regular monitoring of water quality parameters[174]. - The company has implemented measures to control noise pollution, ensuring compliance with relevant noise emission standards[176]. - The company has established a hazardous waste storage facility that meets regulatory requirements and has signed agreements with qualified disposal companies for waste management[176]. - Total donations amounted to 724,000 CNY, with 668,200 CNY in cash contributions[179]. Shareholder Relations and Dividends - The company has committed to a three-year shareholder return plan for 2023-2025, which was approved in the extraordinary shareholder meeting[131]. - The total cash dividend amount for the current period is CNY 91,287,633.06, which represents 40.82% of the net profit attributable to ordinary shareholders[163]. - The company plans to distribute dividends in cash, stock, or a combination of both, with a minimum cash distribution of 10% of the distributable profit for the year if there are no major investment plans or cash expenditures[157]. - The cash dividend distribution ratio is set at a minimum of 80% for mature companies without major expenditures, 40% for mature companies with major expenditures, and 20% for growth-stage companies with major expenditures[158]. - Over the last three accounting years, the cumulative cash dividend amount is CNY 344,864,391.56, with an average annual net profit of CNY 334,106,127.64, resulting in a cash dividend ratio of 103.22%[165].